Build Versus Buy in the Current Biotech Market Environment - How current economic conditions affect your build-or-buy decision. - BioPharm International

ADVERTISEMENT

Build Versus Buy in the Current Biotech Market Environment
How current economic conditions affect your build-or-buy decision.


BioPharm International
Volume 23, Issue 9

ARE CMOS THE ANSWER?

An alternative to building or retrofitting a facility is to partner with a CMO. Indeed, innovator companies have started looking at the strategic benefits of engaging CMOs to support their products throughout their lifecycle: in general, it is likely that the CMO's facility and quality systems already meet regulatory requirements, including international regulations; an innovator company can choose a CMO in a particular location (or locations) as there continues to be significant CMO business development in Singapore, Israel, Japan, and the BRIC countries (Brazil, Russia, India, and China); CMOs are differentiating themselves by increasingly offering specialized technologies and services, and several major CMOs are engaging the innovator companies by exploring alternative business models. In addition, companies have access to CMOs that are already prepared to not only manufacture a myriad of products, but also provide you with technologies and personnel already in place to "hit the ground running" in support of your project needs.

Expression Systems

One of the benefits of working with a CMO is that in some instances the IP holder for a particular expression system is the CMO (for example, G-Pex/Catalent; GS/Lonza; BI-HEX/Boheringer Ingelhiem; CHEF-1/CMC Biologics), or a technology may be available to the CMO (SURE (Selexis), UCOE (Millipore)/Eden Biodesign) and accessing it through the CMO may allow your company to obtain preferential business terms. Discussion of available options that may be most appropriate for the production of your product should be based on your company's supply requirements (current and future); your available budget; any target product delivery date(s); and your company's risk tolerance and regulatory strategy.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Compounding Pharmacy Issues Recall, But Challenges FDA Decision
July 22, 2014
AbbVie's Acquisition of Shire Could Save $8 Billion in Taxes
July 21, 2014
AbbVie to Acquire Shire for $54.7 Billion
July 18, 2014
AstraZeneca Reveals Design for New Global R&D Center and Corporate Headquarters
July 18, 2014
Particulate Matter Prompts Baxter's Recall of IV Solutions
July 17, 2014
Author Guidelines
Source: BioPharm International,
Click here